Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Tabloid, Purinethol
6-Thioguanine (6-TG) is an antineoplastic antimetabolite used primarily in the treatment of acute lymphoblastic leukemia (ALL), particularly in maintenance therapy. It is a purine analog that disrupts DNA and RNA synthesis, leading to cell death. 6-TG is often used in combination with other chemotherapy drugs. It belongs to the thiopurine class and is considered a cytotoxic agent.
Used primarily in maintenance therapy for acute lymphoblastic leukemia (ALL).
6-Thioguanine may cause myelosuppression, resulting in potentially fatal bleeding or infections. Hepatotoxicity, including fatal/life-threatening hepatic necrosis and veno-occlusive disease, can occur. Secondary malignancies, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), have been reported. Patients with inherited TPMT deficiency are at increased risk for severe myelosuppression.
Outcome:
Severe myelosuppression
Mechanism:
Inhibition of xanthine oxidase, leading to increased 6-TG levels.
Outcome:
Increased risk of gastrointestinal bleeding
Mechanism:
Additive effects on platelet function.
Outcome:
Reduced absorption of 6-TG
Mechanism:
Changes in stomach pH.
Most likely new formulation: Targeted nanoparticle delivery system for reduced systemic toxicity (Year: 2028, 60% confidence)
Based on historical data and current clinical trial activity, there is a 70% likelihood that 6-TG will remain a key component of ALL maintenance therapy regimens for the next 5 years.
Antineoplastic, Antimetabolite, Purine Analog
Thiopurine